+44 (0) 20 7079 4399
Call HCA from 8am-8pm Mon-Fri and 9am-5pm Sat
HCA Healthcare UK
Professor Angus George Dalgleish
MD FRACP FRCP FRCPath FMedSci
Skin cancers, Hepatobiliary and/or pancreatic cancers, Urological cancers
Kidney, pancreatic and prostate cancers, Melanoma (chemotherapy)
Professor Angus Dalgleish studied medicine at University College London where he obtained an MBBS and a BSc in Anatomy. He is a Fellow of The Royal College of Physicians of the UK and Australia, Royal College of Pathologists and The Academy of Medical Scientists. After graduating and house jobs in London and Poole, he spent a year in the flying doctor service in Queensland. He also trained in Internal Medicine and Oncology in Brisbane and Sydney. Having developed an interest in how viruses caused cancer, he commenced an MD with Professor Robin Weiss, FRS at the Institute of Cancer Research and Royal Marsden Hospital. Following five years as a clinical scientist at the MRC's clinical research centre in Northwick Park, Professor Delgleish was appointed to the Foundation Chair in Oncology at St George's University of London in 1991. There his main interest has been the immunology of cancer and the development of immunotherapies to treat, in particular, melanoma. He is a co-founder of Onyvax, a company set up in 1998 to make novel vaccines for common solid tumours, where he is currently Research Director. Professor Dalgleish currently sits on eight editorial boards, and is the author or co-author of peer reviewed scientific papers and over 70 chapters in medical books. He is the co-editor of five medical books and has been on numerous grant committees and is currently on the European Commission Cancer Board.
To Make an appointment, call HCA on +44(0)20 7079 4399
or click here
Call the contact centre
+44 (0) 20 7079 4399
8am-8pm Mon-Fri, 9am-5pm Sat
Let us call you backCan we call you back at a more convenient time
Email contact centreSend us an email and we will get back to you.
© copyright 2008 - 2017 HCA Healthcare UK.
Registered Name: HCA International Limited; The part of the UK in which it is registered: England and Wales;
Registered Number: 03020522; Registered Office Address: 242 Marylebone Road London NW1 6JL.
£500m has been invested by HCA International in the latest medical technologies and facilities over the last 10 years.
Your hospital will be one of our world-class private hospitals: HCA’s world-class hospitals are accredited by The CHKS Accreditation Unit, a leading provider of healthcare intelligence and quality improvement services. The accreditation is a measure of the overall quality of a hospital and hospitals with CHKS accreditation have been shown to provide a better quality of service.
Your safety will be protected because we have more critical care beds than any other private hospital group: HCA hospitals achieved 100% compliance with all Care Quality Commission inspected outcomes of care in 2011.
Your treatment will be undertaken using the most advanced diagnostic and treatment facilities: Oliver Wyman, Corporate Accounts: Driving quality and value, January 2012.